BORCS8-MEF2B

Across TCGA pan-cancer cohorts, BORCS8-MEF2B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BORCS8-MEF2B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher BORCS8-MEF2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BORCS8-MEF2B expression acts as an unfavorable survival marker.

ESCA are the cancer types where BORCS8-MEF2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.222	0.680	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

BORCS8-MEF2B–ESCA (OS)

Open the ESCA breakdown →